Dendritic cells for cancer immunotherapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The mainstay of cancer treatment remains surgery, radiotherapy, and cytotoxic chemotherapy, which are associated with significant side effects. Cancer immunotherapy, the manipulation of the immune system to eliminate tumor cells, has been considered for several decades as an alternative to these therapies. Among immunotherapeutic modalities, the perspective of using dendritic cell vaccines to stimulate antitumor immunity has shown some promises but also limitations. Dendritic cells are the most potent antigen-presenting cells of the immune system, playing a pivotal role in the initiation and regulation of tumor-specific immune responses as they are endowed with the unique ability to take up, process, and present tumor antigens to CD4<sup>+</sup> or CD8<sup>+</sup> T lymphocytes. Dendritic cells also contribute to the activation of natural killer cells and to the orchestration of humoral immunity. This unique capability has been widely exploited in cancer vaccination approaches against a variety of malignancies. However, tumors commonly develop so-called immune escape mechanisms including the secretion of immunosuppressive -molecules and/or the promotion of immunosuppressive cells such as regulatory T cells that impair dendritic cell functions and therefore compromise the success of dendritic cell vaccination. Specific radio- or chemoimmunotherapeutic manipulations can blunt tolerogenic cells and revert the cancer-induced immunosuppressive environment into a pro-inflammatory context that can enhance dendritic cell capability to effectively prime and sustain antitumor immune responses.

Original languageEnglish (US)
Title of host publicationEmerging Trends in Cell and Gene Therapy
PublisherHumana Press Inc.
Pages251-270
Number of pages20
ISBN (Print)9781627034173, 1627034161, 9781627034166
DOIs
StatePublished - Dec 1 2013

Fingerprint

Immunotherapy
Dendritic Cells
Immunosuppressive Agents
Tumors
Neoplasms
T-cells
Immune system
Immune System
Vaccination
Oncology
Chemotherapy
Radiotherapy
Neoplasm Antigens
Surgery
Antigen-Presenting Cells
Regulatory T-Lymphocytes
Vaccines
Complementary Therapies
Humoral Immunity
Chemical activation

Keywords

  • Antigen-presenting cells
  • Cancer
  • Dendritic cells
  • Immunosurveillance
  • Immunotherapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Larmonier, N., & Katsanis, E. (2013). Dendritic cells for cancer immunotherapy. In Emerging Trends in Cell and Gene Therapy (pp. 251-270). Humana Press Inc.. https://doi.org/10.1007/978-1-62703-417-3_11

Dendritic cells for cancer immunotherapy. / Larmonier, Nicolas; Katsanis, Emmanuel.

Emerging Trends in Cell and Gene Therapy. Humana Press Inc., 2013. p. 251-270.

Research output: Chapter in Book/Report/Conference proceedingChapter

Larmonier, N & Katsanis, E 2013, Dendritic cells for cancer immunotherapy. in Emerging Trends in Cell and Gene Therapy. Humana Press Inc., pp. 251-270. https://doi.org/10.1007/978-1-62703-417-3_11
Larmonier N, Katsanis E. Dendritic cells for cancer immunotherapy. In Emerging Trends in Cell and Gene Therapy. Humana Press Inc. 2013. p. 251-270 https://doi.org/10.1007/978-1-62703-417-3_11
Larmonier, Nicolas ; Katsanis, Emmanuel. / Dendritic cells for cancer immunotherapy. Emerging Trends in Cell and Gene Therapy. Humana Press Inc., 2013. pp. 251-270
@inbook{efaf9ccb5a5e41f49c026d60399fcac4,
title = "Dendritic cells for cancer immunotherapy",
abstract = "The mainstay of cancer treatment remains surgery, radiotherapy, and cytotoxic chemotherapy, which are associated with significant side effects. Cancer immunotherapy, the manipulation of the immune system to eliminate tumor cells, has been considered for several decades as an alternative to these therapies. Among immunotherapeutic modalities, the perspective of using dendritic cell vaccines to stimulate antitumor immunity has shown some promises but also limitations. Dendritic cells are the most potent antigen-presenting cells of the immune system, playing a pivotal role in the initiation and regulation of tumor-specific immune responses as they are endowed with the unique ability to take up, process, and present tumor antigens to CD4+ or CD8+ T lymphocytes. Dendritic cells also contribute to the activation of natural killer cells and to the orchestration of humoral immunity. This unique capability has been widely exploited in cancer vaccination approaches against a variety of malignancies. However, tumors commonly develop so-called immune escape mechanisms including the secretion of immunosuppressive -molecules and/or the promotion of immunosuppressive cells such as regulatory T cells that impair dendritic cell functions and therefore compromise the success of dendritic cell vaccination. Specific radio- or chemoimmunotherapeutic manipulations can blunt tolerogenic cells and revert the cancer-induced immunosuppressive environment into a pro-inflammatory context that can enhance dendritic cell capability to effectively prime and sustain antitumor immune responses.",
keywords = "Antigen-presenting cells, Cancer, Dendritic cells, Immunosurveillance, Immunotherapy",
author = "Nicolas Larmonier and Emmanuel Katsanis",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/978-1-62703-417-3_11",
language = "English (US)",
isbn = "9781627034173",
pages = "251--270",
booktitle = "Emerging Trends in Cell and Gene Therapy",
publisher = "Humana Press Inc.",

}

TY - CHAP

T1 - Dendritic cells for cancer immunotherapy

AU - Larmonier, Nicolas

AU - Katsanis, Emmanuel

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The mainstay of cancer treatment remains surgery, radiotherapy, and cytotoxic chemotherapy, which are associated with significant side effects. Cancer immunotherapy, the manipulation of the immune system to eliminate tumor cells, has been considered for several decades as an alternative to these therapies. Among immunotherapeutic modalities, the perspective of using dendritic cell vaccines to stimulate antitumor immunity has shown some promises but also limitations. Dendritic cells are the most potent antigen-presenting cells of the immune system, playing a pivotal role in the initiation and regulation of tumor-specific immune responses as they are endowed with the unique ability to take up, process, and present tumor antigens to CD4+ or CD8+ T lymphocytes. Dendritic cells also contribute to the activation of natural killer cells and to the orchestration of humoral immunity. This unique capability has been widely exploited in cancer vaccination approaches against a variety of malignancies. However, tumors commonly develop so-called immune escape mechanisms including the secretion of immunosuppressive -molecules and/or the promotion of immunosuppressive cells such as regulatory T cells that impair dendritic cell functions and therefore compromise the success of dendritic cell vaccination. Specific radio- or chemoimmunotherapeutic manipulations can blunt tolerogenic cells and revert the cancer-induced immunosuppressive environment into a pro-inflammatory context that can enhance dendritic cell capability to effectively prime and sustain antitumor immune responses.

AB - The mainstay of cancer treatment remains surgery, radiotherapy, and cytotoxic chemotherapy, which are associated with significant side effects. Cancer immunotherapy, the manipulation of the immune system to eliminate tumor cells, has been considered for several decades as an alternative to these therapies. Among immunotherapeutic modalities, the perspective of using dendritic cell vaccines to stimulate antitumor immunity has shown some promises but also limitations. Dendritic cells are the most potent antigen-presenting cells of the immune system, playing a pivotal role in the initiation and regulation of tumor-specific immune responses as they are endowed with the unique ability to take up, process, and present tumor antigens to CD4+ or CD8+ T lymphocytes. Dendritic cells also contribute to the activation of natural killer cells and to the orchestration of humoral immunity. This unique capability has been widely exploited in cancer vaccination approaches against a variety of malignancies. However, tumors commonly develop so-called immune escape mechanisms including the secretion of immunosuppressive -molecules and/or the promotion of immunosuppressive cells such as regulatory T cells that impair dendritic cell functions and therefore compromise the success of dendritic cell vaccination. Specific radio- or chemoimmunotherapeutic manipulations can blunt tolerogenic cells and revert the cancer-induced immunosuppressive environment into a pro-inflammatory context that can enhance dendritic cell capability to effectively prime and sustain antitumor immune responses.

KW - Antigen-presenting cells

KW - Cancer

KW - Dendritic cells

KW - Immunosurveillance

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84929868006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929868006&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-417-3_11

DO - 10.1007/978-1-62703-417-3_11

M3 - Chapter

AN - SCOPUS:84929868006

SN - 9781627034173

SN - 1627034161

SN - 9781627034166

SP - 251

EP - 270

BT - Emerging Trends in Cell and Gene Therapy

PB - Humana Press Inc.

ER -